Only months after the company acknowledged that the shot causes a rare but dangerous side effect, the Oxford-AstraZeneca coronavirus vaccine may be discontinued worldwide. AstraZeneca, however, insists that the decision to pull the vaccine was simply made for business reasons.
AstraZeneca pulled its “marketing approval” for its COVID- 19 vaccine, known economically as Vaxzevria, in the European Union on Tuesday and strategies to do so in the UK and other countries where it was deployed in the coming weeks. The decision wo n’t have an impact on the US, where the jab was never approved for commercial use.
The medical giant claimed that the decision was made for business reasons, noting that the vaccine is no longer being produced and that more new vaccines have been created to treat tale Chinese virus strains.
AstraZeneca made the decision after it was revealed in court records that the jab might lead to the uncommon but risky side effect of thrombosis with thrombocytopenia syndrome ( TTS), which can lead to blood clots and low blood platelets. The vaccine has been tied to at least 81 incidents in the UK, only, in addition to plenty of accidents in the country, The Telegraph information.
In a case brought by 51 alleged vaccine patients seeking up to £100 million in damages at Britain’s High Court,  , AstraZeneca said that its , Covid immunization” is, in very rare circumstances, cause TTS”.
Earlier in the 2021 year, several European countries began suspending the use of the AstraZeneca jab in response to reports of heart clot-related fatalities that were thought to be related to the vaccine.  , The European Medicines Agency, which serves as Europe’s major drug regulator, said in April of 2021 that while it had found a “possible website” between the vaccine and “unusual blood clots with low blood cells”, it found that the benefits of the shot also outweighed the challenges.
By the second quarter of 2021, the American government had distributed 50 million photos, and the autumn booster shot strategy campaign had been replaced with jabs produced by Pfizer and Moderna. In 2023, Britain’s recognized researcher said , there is “evidence of an increase in cardiovascular death in younger women after a second dose of quasi- mRNA vaccines, with the risk being 3.5 times higher in the 12 weeks following vaccination, compared with the longer- term risk”.
Due to the cost of producing the vaccines, billions of AstraZeneca shots were distributed to developing countries through a UN program. However, many countries still switched to MRNA alternatives.
According to new recommendations from health technocrats, the majority of Britons under the age of 40 will be given options for the Oxford-AstraZeneca vaccine due to blood clot connections. https ://t.co/KIyh8QcESB
— Breitbart News ( @BreitbartNews ) May 8, 2021
The decision to withdraw the marketing authorization, which would end the use of the AstraZeneca vaccine in the EU, was welcomed, according to Sarah Moore of the Leigh Day law firm representing alleged victims in the UK.
It will be seen as a decision in light of AstraZeneca’s recent admission that the vaccine can cause TTS and the fact that global regulators suspended or curbed use of the vaccine due to concerns about TTS.
” This is an important regulatory step, but still our clients remain without fair compensation. We will continue to fight for the reform of the vaccine-damage compensation system and support its implementation.
The pharmaceutical company claimed that the decision to forego the jab’s authorisation had nothing to do with the situation, saying in a statement to The Telegraph:” We are incredibly proud of the role Vaxzevria played in ending the global pandemic. Over 6.5 million lives were saved in the first year of use, according to independent estimates, and more than 3 billion doses were distributed globally.
Governments around the world have recognized our efforts, and they are regarded as essential components in putting an end to the pandemic.
” As multiple, variant Covid- 19 vaccines have since been developed, there is a surplus of available updated vaccines. Due to this, Vaxzevria’s demand has decreased and is no longer being produced or supplied. Therefore, AstraZeneca made the decision to start removing Vaxzevria’s marketing authorizations within Europe.
We will now work with our partners and regulators to come up with a solid course of action to bring this chapter’s significant contribution to the Covid-19 pandemic to its conclusion.
UK Govt Data: Young Women Who Took AstraZeneca Vax Had 3.5 Times Higher Risk of Heart Death https ://t.co/OamDG7zymC
— Breitbart London ( @BreitbartLondon ) April 1, 2023
